Compounds > n,n,n'-trimethyl-n'-(2-hydroxy-3-methyl-5-iodobenzyl)-1,3-propanediamine
Page last updated: 2024-09-03

n,n,n'-trimethyl-n'-(2-hydroxy-3-methyl-5-iodobenzyl)-1,3-propanediamine and Cancer of Pancreas

n,n,n'-trimethyl-n'-(2-hydroxy-3-methyl-5-iodobenzyl)-1,3-propanediamine has been researched along with Cancer of Pancreas in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Aoki, E; Fujita, T; Konishi, J; Kubo, S; Saji, H; Shibata, T; Yamamoto, K; Yokoyama, A; Yonekura, Y1

Other Studies

1 other study(ies) available for n,n,n'-trimethyl-n'-(2-hydroxy-3-methyl-5-iodobenzyl)-1,3-propanediamine and Cancer of Pancreas

ArticleYear
Human pancreas scintigraphy using iodine-123-labeled HIPDM and SPECT.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1990, Volume: 31, Issue:6

    Topics: Adult; Aged; Cholangiopancreatography, Endoscopic Retrograde; Chronic Disease; Female; Humans; Iodine Radioisotopes; Iodobenzenes; Male; Middle Aged; Pancreatic Neoplasms; Pancreatitis; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; Ultrasonography

1990